Yahoo Finance Transparency Notification
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION |
Acacia Pharma Group plc
1. Summary of the notification
Cambridge, UK and Indianapolis, US – 26 February 2021, 08:00 CET: Acacia Pharma Group plc has received a transparency notification dated 23 February 2021 indicating that Cosmo Pharmaceuticals N.V now holds, by virtue of the issue of shares on 23 February 2021, 19.66% of the voting rights of the company. Cosmo has therefore crossed the threshold of 20%.
2. Content of notification
The notification dated 23 February 2021 contains the following information:
Reason of the notification – passive crossing of a threshold
Notification by – a parent undertaking or a controlling person
Persons subject to the notification requirement – Cosmo Pharmaceuticals N.V. Riverside 2, Sir John Rogerson’s Quay, Dublin 2, Ireland
Date on which the threshold is crossed – 23 February 2021
Threshold that is crossed – 20%
Denominator – 99,689,451
Notified details:
A) Voting rights | Previous notification | After the transaction | |||
# of voting rights | # of voting rights | % of voting rights | |||
Holders of voting rights | Linked to securities | Not linked to securities | Linked to securities | Not linked to securities | |
Cosmo Pharmaceuticals N.V. | 0 | 0 | 0 | 0.00% | 0.00% |
Cosmo Technologies Ltd. | 19,600,098 | 19,600,098 | 0 | 19.66% | 0.00% |
Subtotal | 19,600,098 | 19,600,098 | 19.66% | ||
TOTAL | 19,600,098 | 0 | 19.66% | 0.00% | |
B) Voting rights | After the transaction | |||||
Holders of equivalent financial instruments | Type of financial instrument | Expiration date | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement |
TOTAL | 0 | 0.00% | ||||
TOTAL (A+B) | # of voting rights | % of voting rights | ||||
CALCULATE | 19,600,098 | 19.66% | ||||
·Full chain of controlled undertakings through which the holding is effectively held: Cosmo Technologies Ltd is a 100% subsidiary of Cosmo Pharmaceuticals N.V.
Miscellaneous
This press release is available on Acacia Pharma Group plc’s website (https://acaciapharma.com/investors/regulatory-announcements)
The notification may be found on Acacia Pharma Group plc’s website ((https://acaciapharma.com/investors/regulatory-announcements)
Contacts
Acacia Pharma Group plc | International Media |
US Investors | Media in Belgium and the Netherlands |
Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).
BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.
www.acaciapharma.com
Attachment
